Imaging studies of biodistribution and kinetics in drug development

被引:16
|
作者
Berridge, MS
Heald, DL
Lee, Z
机构
[1] 3D Imaging, Oakwood Village, OH 44146 USA
[2] Univ Hosp Cleveland, Cleveland, OH 44106 USA
[3] Case Western Reserve Univ, Cleveland, OH 44106 USA
[4] Aventis Pharmaceut Inc, Bridgewater, NJ USA
关键词
imaging; drug development; radionuclide; oral; pulmonary;
D O I
10.1002/ddr.10220
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Although the intravenous route of administration is rarely used for drugs, it is by far the most common route for PET and SPECT radiotracers. This article discusses the use of planar and tomographic nuclear medicine technologies to image and quantify the distribution of drugs after local administration. In principle, this would include topical dermatologic, otic, ophthalmic, rectal, and vaginal administration, as well as the intramuscular, oral, and inhalation routes, although precedents do not yet exist for all of these. The studies reviewed focus mainly on oral ingestion and oral and nasal inhalation. The use of nondrug tracers for formulations is discussed, principally with planar imaging or SPECT using radionuclides such as Tc-99m, as well as PET imaging where the active ingredient of a formulation can be labeled with C-11 or sometimes F-18. An example of the latter type is a study of the deposition and kinetics in the lungs and airways of triamcinolone acetonide, an anti inflammatory steroid used for topical treatment of allergic rhinitis and asthma, dispensed from an inhaler. PET has high potential for evaluation of different formulations and delivery devices in the development of topically applied drugs. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:208 / 226
页数:19
相关论文
共 50 条
  • [31] Imaging as a tool in drug development
    Strack, Thomas
    [J]. DRUGS OF TODAY, 2007, 43 (10) : 725 - 736
  • [32] Molecular imaging in drug development
    Kassiou, Michael
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (01) : 1 - 1
  • [33] Atherosclerosis imaging in drug development
    Nicholls, Stephen J.
    Kalidindi, Srinivasa
    Moon, Keon-Woong
    Nissen, Steven E.
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (09) : 1241 - 1250
  • [34] MOLECULAR IMAGING FOR DRUG DEVELOPMENT
    Watanabe, Yasuyoshi
    [J]. DRUG METABOLISM REVIEWS, 2014, 45 : 21 - 22
  • [35] CLINICAL IMAGING IN DRUG DEVELOPMENT
    Hoekstra, O.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 22 - 22
  • [36] Molecular Imaging in drug development
    Agarwal, Amit
    [J]. GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2007, 27 (15): : 66 - 67
  • [37] The role of imaging in drug development
    Mccarthy, T. J.
    [J]. QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 53 (04): : 382 - 386
  • [38] Verapamil-Loaded Cubosomes for Enhancing Intranasal Drug Delivery: Development, Characterization, Ex Vivo Permeation, and Brain Biodistribution Studies
    Faisal, Mennatullah M.
    Gomaa, Eman
    Ibrahim, Adel Ehab
    El Deeb, Sami
    Al-Harrasi, Ahmed
    Ibrahim, Tarek M.
    [J]. AAPS PHARMSCITECH, 2024, 25 (05)
  • [39] Biodistribution and in vitro drug release kinetics of a radiolabeled paclitaxel-monoclonal antibody conjugate.
    Safavy, A
    Ainsworth, SK
    Helson, L
    McChesney, JD
    Khazaeli, MB
    Safavy, K
    Bonner, JA
    Buchsbaum, DJ
    [J]. CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6194S - 6194S
  • [40] Radiolabeling, quality control, biodistribution, and imaging studies of 177Lu-ibandronate
    Xu, Qin
    Zhang, Shumao
    Zhao, Yan
    Feng, Yue
    Liu, Lin
    Cai, Liang
    Zhang, Wei
    Huang, Zhanwen
    Wei, Hongyuan
    Zhuo, Liangang
    Chen, Yue
    [J]. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 (01): : 43 - 51